These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1696 related items for PubMed ID: 24504054

  • 1. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
    Heusch P, Buchbender C, Köhler J, Nensa F, Gauler T, Gomez B, Reis H, Stamatis G, Kühl H, Hartung V, Heusner TA.
    J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
    [Abstract] [Full Text] [Related]

  • 2. Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer.
    Kirchner J, Sawicki LM, Nensa F, Schaarschmidt BM, Reis H, Ingenwerth M, Bogner S, Aigner C, Buchbender C, Umutlu L, Antoch G, Herrmann K, Heusch P.
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):437-445. PubMed ID: 30074073
    [Abstract] [Full Text] [Related]

  • 3. Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
    Heusch P, Köhler J, Wittsack HJ, Heusner TA, Buchbender C, Poeppel TD, Nensa F, Wetter A, Gauler T, Hartung V, Lanzman RS.
    Eur J Radiol; 2013 Nov; 82(11):2055-60. PubMed ID: 23830904
    [Abstract] [Full Text] [Related]

  • 4. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H, Brendle C, Schraml C, Martirosian P, Bezrukov I, Hetzel J, Müller M, Sauter A, Claussen CD, Pfannenberg C, Schwenzer NF.
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [Abstract] [Full Text] [Related]

  • 5. PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT.
    Rauscher I, Eiber M, Fürst S, Souvatzoglou M, Nekolla SG, Ziegler SI, Rummeny EJ, Schwaiger M, Beer AJ.
    J Nucl Med; 2014 May; 55(5):724-9. PubMed ID: 24652827
    [Abstract] [Full Text] [Related]

  • 6. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 7. Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer - does it change therapeutic decisions in comparison to 18F-FDG PET/CT?
    Schaarschmidt BM, Grueneisen J, Metzenmacher M, Gomez B, Gauler T, Roesel C, Heusch P, Ruhlmann V, Umutlu L, Antoch G, Buchbender C.
    Eur Radiol; 2017 Feb; 27(2):681-688. PubMed ID: 27180186
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y.
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [Abstract] [Full Text] [Related]

  • 9. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
    Park SY, Cho A, Yu WS, Lee CY, Lee JG, Kim DJ, Chung KY.
    J Nucl Med; 2015 Jan; 56(1):45-9. PubMed ID: 25525185
    [Abstract] [Full Text] [Related]

  • 10. N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT.
    Ohno Y, Koyama H, Yoshikawa T, Nishio M, Aoyama N, Onishi Y, Takenaka D, Matsumoto S, Maniwa Y, Nishio W, Nishimura Y, Itoh T, Sugimura K.
    Radiology; 2011 Nov; 261(2):605-15. PubMed ID: 21926377
    [Abstract] [Full Text] [Related]

  • 11. Diagnostic accuracy of virtual 18F-FDG PET/CT bronchoscopy for the detection of lymph node metastases in non-small cell lung cancer patients.
    Herbrik M, Treffert J, Geiger B, Riegger C, Hartung V, Rosenbaum-Krumme SJ, Forsting M, Antoch G, Heusner TA.
    J Nucl Med; 2011 Oct; 52(10):1520-5. PubMed ID: 21908390
    [Abstract] [Full Text] [Related]

  • 12. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
    Heusch P, Buchbender C, Köhler J, Nensa F, Beiderwellen K, Kühl H, Lanzman RS, Wittsack HJ, Gomez B, Gauler T, Schuler M, Forsting M, Bockisch A, Antoch G, Heusner TA.
    Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
    [Abstract] [Full Text] [Related]

  • 13. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C, Raderer M, Karanikas G, Weber M, Kiesewetter B, Dolak W, Simonitsch-Klupp I, Mayerhoefer ME.
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the Outcome of Lung Nodules Missed on 18F-FDG PET/MRI Compared with 18F-FDG PET/CT in Patients with Known Malignancies.
    Sawicki LM, Grueneisen J, Buchbender C, Schaarschmidt BM, Gomez B, Ruhlmann V, Umutlu L, Antoch G, Heusch P.
    J Nucl Med; 2016 Jan; 57(1):15-20. PubMed ID: 26514173
    [Abstract] [Full Text] [Related]

  • 15. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in lymph node metastases of non-small cell lung cancer (NSCLC) patients using hybrid 18F-FDG PET/MRI.
    Schaarschmidt BM, Buchbender C, Nensa F, Grueneisen J, Gomez B, Köhler J, Reis H, Ruhlmann V, Umutlu L, Heusch P.
    PLoS One; 2015 Jan; 10(1):e0116277. PubMed ID: 25574968
    [Abstract] [Full Text] [Related]

  • 16. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
    Huang WY, Kao CH, Huang WS, Chen CM, Chang LP, Lee MS, Chao HL, Chiu CH, Lo CH, Jen YM.
    J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
    [Abstract] [Full Text] [Related]

  • 17. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT.
    Sauter AW, Winterstein S, Spira D, Hetzel J, Schulze M, Mueller M, Pfannenberg C, Claussen CD, Klotz E, Hann von Weyhern C, Horger MS.
    J Nucl Med; 2012 Apr; 53(4):521-9. PubMed ID: 22414637
    [Abstract] [Full Text] [Related]

  • 18. Interobserver variability among measurements of the maximum and mean standardized uptake values on (18)F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors.
    Huang YE, Chen CF, Huang YJ, Konda SD, Appelbaum DE, Pu Y.
    Acta Radiol; 2010 Sep; 51(7):782-8. PubMed ID: 20707663
    [Abstract] [Full Text] [Related]

  • 19. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)?
    Regier M, Derlin T, Schwarz D, Laqmani A, Henes FO, Groth M, Buhk JH, Kooijman H, Adam G.
    Eur J Radiol; 2012 Oct; 81(10):2913-8. PubMed ID: 22197090
    [Abstract] [Full Text] [Related]

  • 20. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
    Jensen TK, Holt P, Gerke O, Riehmann M, Svolgaard B, Marcussen N, Bouchelouche K.
    Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 85.